Skip to main content

Table 1 Baseline patient characteristics (n = 50)

From: Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study

Parameter N (%)
Sex, male 29 (58)
Median age at diagnosis, yrs. (range) 56 (41–68)
Diagnosis  
 IgG 20 (40 %)
 IgA 11 (22 %)
 IgD 2 (4 %)
 Light chain 16 (32 %)
 Plasma cell leukemia 1 (2 %)
Durie and Salmon stage  
 IA 2 (4)
 IIA 17 (34)
 IIIA 29 (58)
 IIIB 1 (2)
 Na (a) 1 (2)
ISS stage  
 1 26 (52)
 2 17 (34)
 3 5 (10)
 Na (a) 1 (2)
Cytogenetic analysis [21]  
 High risk 6 (12 %)
 Intermediate risk 8 (16 %)
 Standard risk 35 (70 %)
 Na (a) 1 (2 %)
Induction treatment  
 VAD (b) 23 (46)
 Novel agents (c) 27 (54)
Up-front tandem ASCT (d) 50 (100)
  1. (a) Na not available. (b) VAD Vincristine, Adryamicin, Dexamethasone (2 courses). (c) Novel agents: Bortezomib-based regimes (n = 21, 3 courses), Immunomodulators only (n = 6, 3 courses). (d) ASCT autologous stem cell transplant